menu ☰
menu ˟

[Comment] Dual antiplatelet therapy and non-cardiovascular mortality

16 Nov 2014

According to recent guidelines from the European Society of Cardiology,1 dual antiplatelet therapy should be pursued for 6–12 months after acute coronary syndromes or drug-eluting stent implantation; thereafter, patients should be switched to single antiplatelet therapy. However, the optimum length of dual antiplatelet therapy in patients with stable coronary artery disease is highly controversial. Recurrent events might be due to either new-plaque rupture or complications related to previous revascularisations, and it has been suggested that extended dual antiplatelet therapy could protect patients with stable coronary artery disease even beyond 1 year after percutaneous coronary intervention.

Click here to view the full article which appeared in The Lancet